There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

A bottleneck in ensuring access to widespread molecular diagnostics, especially in low- and middle-income countries, has been ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with other smoking cessation treatments.

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.